Clinical benefit from ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels

Clinical benefit from ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels

Stage IV metastatic melanoma patients historically have a poor prognosis with 5-10% 5-year survival. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA4), is one of the first treatments to provide beneficial durable responses in advanced melanoma. However, less than 25...

Full description

Bibliographic Details
Main Authors: Anna M. Leung, Agnes Fermin Lee, Junko eOzao-Choy, Romela Irene Ramos, Omid eHamid, Steven J. O'Day, Myung eShin-Sim, Donald L. Morton, Mark B. Faries, Peter A. Sieling, Delphine J Lee
Format: Article
Language:English
Published: Frontiers Media S.A. 2014-05-01
Series:Frontiers in Oncology
Subjects:
Serum
Survival
ipilimumab
Metastatic Melanoma
Response to therapy
soluble CTLA4
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00110/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00110/full

Similar Items